Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012Cited by 12.6k
PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyDung T. Le, Luis A. Díaz, Jennifer N. Uram et al.|New England Journal of Medicine|2015Cited by 9.4k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Luis A. Díaz, Jennifer N. Durham et al.|Science|2017Cited by 6.6k
Fulminant Myocarditis with Combination Immune Checkpoint BlockadeDouglas B. Johnson, Javid J. Moslehi, Justin M. Balko et al.|New England Journal of Medicine|2016Cited by 2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L. Topalian, F. Stephen Hodi, Mario Sznol et al.|Journal of Clinical Oncology|2014Cited by 2.2k